The Peptide Therapy Market is witnessing steady expansion as pharmaceutical companies increasingly explore peptide-based solutions for chronic and complex diseases. WiseGuyReports estimates that the market will grow from USD 37.9 billion in 2025 to USD 65.0 billion by 2035, representing a CAGR of 5.5%.

One of the major trends shaping the industry is the increasing adoption of targeted therapies. Peptides can offer selective interactions with biological targets, making them attractive for applications in metabolic disorders, oncology, cardiovascular diseases, and hormonal conditions. The growing emphasis on personalized medicine is further encouraging research into peptide-based treatments.

Technological improvements in peptide synthesis, formulation, and drug-delivery systems are also creating new opportunities. Researchers are exploring modified peptides and alternative administration methods to improve stability, efficacy, convenience, and patient compliance.

The market is segmented into synthetic, natural, and modified peptides, while administration routes include injectable, oral, and transdermal formulations. Hospitals, specialty clinics, and research laboratories represent major end-use segments.

North America currently benefits from strong healthcare infrastructure and pharmaceutical research, while Asia Pacific is projected to experience rapid development because of increasing healthcare investment and improving access to advanced therapies.

Future opportunities are expected to emerge from novel peptide drug development, biotechnology partnerships, personalized treatment approaches, and expanding applications in oncology and metabolic disorders.